A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies

The spectrum and pattern of p53 mutations detected in 42 cases of B-cell chronic lymphocytic leukemia (B-CLL) were analyzed, and several interesting features were noted. Codon 209 in the p53 gene may be a new hot-spot for p53 mutation in B-CLL disease. Four of the 42 (10%) reported B-CLL p53 mutations occurred at codon 209 versus none in 214 cases of other lymphoid malignancies screened for p53 mutations (P = 0.0006). Transversion mutations predominated at codon 273 rather than the transition mutations that are known to occur at this CpG site. Four of six (67%) B-CLL cases had transversions at codon 273 compared with two of 17 (12%) of all other lymphoid tumors examined (P = 0.02). In addition, over 65% of the p53 mutations detected in B-CLL showed a strand bias for p53 mutations on the untranscribed DNA strand. This feature of DNA strand bias is notable in cancers of the lung, esophagus, and head and neck, which may result from high exposure to carcinogens. This spectrum of p53 mutations in B-CLL together with the high frequency of transversion mutations and DNA strand bias may implicate environmental carcinogens associated with p53 gene damage in some B-CLL patients.

Identification of melanoma cell surface antigens immunogenic in mice

Active immunization to B16 melanoma cells or vaccines induces anti-melanoma immune responses in syngeneic mice. The immunogenic antigens stimulating immunity to this tumor have not been identified. In this study we detected several B16 melanoma antigens immunogenic in syngeneic mice using as probes antimelanoma antibodies induced by immunization to B16 melanoma vaccines. These antigens were identified by SDS-PAGE and autoradiographic analysis of specific immunoprecipitates. They were cell-surface components with approximate molecular weights of 41, 46, 50, 75, 80, and 104 KD. All these antigens were expressed by syngeneic and xenogeneic melanomas and by some unrelated syngeneic tumors but not by normal syngeneic cells, xenogeneic melanocytes, or by B16 melanoma cells obtained from fresh tumors or grown in defined medium. The antigens were distinct from murine viral antigens expressed by B16 melanoma cells and from components of the culture medium used to grow cells for vaccine production. These results indicate that several B16 melanoma cell-surface antigens are immunogenic in syngeneic mice. Expression of these antigens appears to be related to malignant transformation as they were found on all melanomas studied, and some other cancers, but not on normal cells.

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

We studied 53 patients with B-cell chronic lymphocytic leukemia (B-CLL) and found mutations of the p53 gene in 15%. Patients with p53 gene mutations were found to have an aggressive form of B-CLL disease characterized by advanced Rai stage, rapid lymphocyte doubling time (LDT), and resistance to chemotherapy. While 27 of 29 treated patients (93%) without p53 mutations achieved a partial remission, only one of seven treated patients (14%) with p53 mutations achieved a partial remission (P = .00009). Adjusting for prognostic factors (age, sex, race, and Rai stage), patients with p53 gene mutations had a 13-fold greater risk of death than patients without p53 mutations (P = .013). In addition to examining the clinical relevance of p53 gene mutations in B-CLL, we investigated the possible role of p53 gene regulation in the expression of the multidrug resistance genes MDR1 and MDR3. We quantitated MDR1 and MDR3 mRNA expression by reverse transcription-polymerase chain reaction (RT-PCR). Expression of both the MDR1 and MDR3 genes was independent of p53 gene mutation or prior drug treatment, and did not predict for clinical response. Our findings indicate that p53 gene mutations in B-CLL are associated with a poor clinical outcome and may be a prognostic indicator for drug resistance.

Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin

Cyclosporin (CsA) is an immunosuppressant which binds to cyclophilin (Cyp). The relationship between Cyp binding and immunosuppression has been questioned since one of the analogs of CsA, N-methyl-L-alanyl6 cyclosporin (methyl-alanyl CsA) binds to Cyp but is not immunosuppressive. We compared the immunosuppressive properties of CsA, methyl-alanyl CsA and o-acetyl-threonine2 cyclosporin (monoacetyl CyC), since monoacetyl CyC does not bind to Cyp when tested in cell-free assays and its immunosuppressive properties had not been tested. Cyp is a peptidyl-prolyl isomerase which is abundant in all human tissues, yet the activities of CsA are mostly confined to inhibition of T cell and thymocyte activation, and to neuro- and nephro-toxicity and are independent of inhibition of the isomerase. Activation of thymocytes and of T cells is regulated by the binding of a nuclear factor(s) (NFs) to the NF-AT region (-285 to -255) of the IL-2 promoter. We studied inhibition of binding to the NF-AT region of NFs derived from primary cultures of thymocytes treated with CsA or its analogs. In addition, we compared the effect of CsA and its analogs on the expression of the IL-2 gene in a stably transfected Jurkat-cell line (Fgl 5) which contains three copies of NF-AT and the reporter enzyme beta-galactosidase; and on inhibition of proliferation induced by concanavalin A (Con A) or IL-2. We found that monoacetyl CyC which does not bind to Cyp is immunosuppressive by our criteria when tested in cultured cells due to either a different mechanism of action or to metabolic activation.

Repopulation potential of thymocytes forming rosettes with phagocytic cells of the thymic reticulum

Thymocytes binding in vitro to phagocytic cells of the thymic reticulum (P-TR), termed 'rosetting thymocytes', were injected intravenously into irradiated congenic mice and their migration patterns were compared with those that do not bind to P-TR, called 'non-rosetting thymocytes', similarly transferred. Donor cells, C57BL/Ka Thy 1.2, were distinguished from recipient cells, C57BL/Ka Thy 1.1 by a direct immunofluorescence technique using an anti-Thy 1.2 monoclonal antibody. The results demonstrate that the rosetting thymocytes have a greater capacity for homing back to the thymus and for populating the mesenteric lymph node and the spleen. Intrathymic transfer assay revealed that the donor-derived cells detected in the peripheral organs were of thymic origin.

Control of prothymocyte proliferation by thymic accessory cells

All thymocyte subpopulations derive from intrathymic precursors which are double negative (DN) for Lyt-2 and L3T4 differentiation antigens. Although nearly half of DN cells express a receptor for interleukin 2 (IL 2R), they respond poorly to IL 2. DN cell proliferation can be obtained in the presence of various exogenous stimuli, but the in vivo signal for DN cell response to IL 2 remains unclear. We show in the present report that phagocytic cells of the thymic reticulum are able to induce the proliferation of DN thymocytes in the presence of recombinant IL 2 (rIL 2). Cell-to-cell contact is needed for this effect. Antibodies directed against class I MHC antigens but not against class II can inhibit DN cell proliferation. DNA-synthetizing cells were labeled by incubation with 10 microM bromodeoxyuridine either before or at various times during the culture period. Bromodeoxyuridine was then detected in the DNA of proliferating cells and/or their progeny already stained with anti-Lyt-2 and L3T4 antibodies. During the initial 16 h and independently of culture conditions, 16-25% of the cells expressed surface antigens and 50-65% of them derived from DN cells which were in S phase just before culture; these differentiated cells had a very short life span. In the second culture period, the presence of both rIL 2 and thymic accessory cells was necessary for cell survival. In these conditions, DN cell number and proliferation rate were constant and a low number of Lyt-2+ and/or L3T4+ cells was continuously generated. Thymic accessory cells therefore appear to provide the signal(s) necessary for IL 2-induced proliferation of thymocyte precursors. Implications of these findings for normal in vivo intrathymic proliferation and differentiation are discussed.

Thymic reticulum in mice. IV. The rosette formation between phagocytic cells of the thymic reticulum and cortical type thymocytes is mediated by complement receptor type three

A phagocytic cell of the thymic reticulum (P-TR) with dendritic shape recently has been isolated and characterized. We have previously shown that P-TR have an important role to play in the constitution of the thymic microenvironment. Indeed, P-TR are able to produce interleukin 1 and prostaglandin E2, both of which regulate thymocyte activation and proliferation. They are able also to stimulate the proliferation of syngeneic thymocytes enriched in the medullary type. In the present paper, we analyze a close relationship which exists between P-TR and thymocytes of the cortical type. About 25% of P-TR are able to bind to thymocytes and to form rosettes. Rosetting thymocytes represent about 5% of the total population and are PNA+, Lyt 1+2+, H-2-, and sensitive to in vivo steroid treatment. Pretreatment of P-TR with anti-Mac-1, a monoclonal rat IgG antibody against mouse macrophages and specific for complement receptor type three (CR3), abolished rosette formation. Rosette formation also was found to be inhibited by zymosan-treated serum containing the CR3 ligand, C3bi, and by certain sugars, in particular, N-acetyl-D-galactosamine and L-xylose. Our results suggest that rosetting thymocytes bind to CR3 on the P-TR membrane and that sugar constituents of the carbohydrate moieties on the thymocyte surface may serve as a recognition site during the binding process.

Thymic reticulum in mice. IV. The rosette formation between phagocytic cells of the thymic reticulum and cortical type thymocytes is mediated by complement receptor type three

A phagocytic cell of the thymic reticulum (P-TR) with dendritic shape recently has been isolated and characterized. We have previously shown that P-TR have an important role to play in the constitution of the thymic microenvironment. Indeed, P-TR are able to produce interleukin 1 and prostaglandin E2, both of which regulate thymocyte activation and proliferation. They are able also to stimulate the proliferation of syngeneic thymocytes enriched in the medullary type. In the present paper, we analyze a close relationship which exists between P-TR and thymocytes of the cortical type. About 25% of P-TR are able to bind to thymocytes and to form rosettes. Rosetting thymocytes represent about 5% of the total population and are PNA+, Lyt 1+2+, H-2-, and sensitive to in vivo steroid treatment. Pretreatment of P-TR with anti-Mac-1, a monoclonal rat IgG antibody against mouse macrophages and specific for complement receptor type three (CR3), abolished rosette formation. Rosette formation also was found to be inhibited by zymosan-treated serum containing the CR3 ligand, C3bi, and by certain sugars, in particular, N-acetyl-D-galactosamine and L-xylose. Our results suggest that rosetting thymocytes bind to CR3 on the P-TR membrane and that sugar constituents of the carbohydrate moieties on the thymocyte surface may serve as a recognition site during the binding process.